Gestational diabetes & diabetes in pregnancy
Continuous Glucose Monitoring and Maternal and Neonatal Morbidity in Pregnant People With Type 1 Diabetes
Authors' conclusion
CGM metrics in the late second to early third trimester, a period of peak insulin resistance, may help to distinguish risk of HDP and LGA in gravidas with T1DM.
Study context
- Population
- Singleton gestations with T1D using Dexcom G6 continuous glucose monitoring (CGM), academic medical center, 2018–2022; preconception median HbA1c 6.5% (IQR 6.0, 7.1), BMI 24.8 kg/m² (IQR 21.9, 27.1)
- Participants
- 87 participants
- Exposure
- CGM metrics by presence vs absence of adverse pregnancy outcomes
- Outcome
- CGM metrics (TIR, TAR, TBR, mean glucose) by adverse pregnancy outcome
- Follow-up
- Weeks 240 to 376
Methodological detailssingle academic medical center
- Single academic medical center
Main finding
As reported in the abstract
- Hypertensive disorders of pregnancy (HDP): higher TAR and mean glucose and lower TIR, weeks 240 to 376
- P < .05
- TIR, TAR and mean glucose evolution differed by HDP status, greatest divergence at 280 to 296 weeks
- P ≤ .001
Observational data: associations, not effects.
Further findings
- Had at least one adverse pregnancy outcome
- 71%
Original publication
Continuous Glucose Monitoring and Maternal and Neonatal Morbidity in Pregnant People With Type 1 Diabetes. J Diabetes Sci Technol. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →